#ScienceLink #Madrid2026 #ESMO26 #DUOE #CancerDeEndometrio
在 DUO-E 的第二次中期分析（III 期；n=718）中，durvalumab + carboplatino/paclitaxel 后序 durvalumab ± olaparib 治疗晚期/复发性子宫内膜癌一线时，SG 数值结果不利。
⏰ 中位随访时间：52 个月
SG 数据成熟度：52%
📊 durvalumab + olaparib 维持治疗 vs 对照
SG：51.1 vs 39.6 个月
HR 0.77（IC 95%：0.60–0.98；p=0.037）
中位数数值差异：11.5 个月。
📊 durvalumab 单药维持治疗 vs 对照
SG：40.7 vs 39.6 个月
HR 0.87（IC 95%：0.68–1.11；p=0.259）
⚠️ 没有任何治疗方案在 SG 上达到统计学显著性。对于 olaparib 组，预设阈值为 p<0.0165。
🧬 探索性亚组：含 olaparib 方案 vs 对照
dMMR：HR 0.43（IC 95%：0.21–0.83）。
pMMR：HR 0.85（IC 95%：0.65–1.11）。
未发现新的安全性信号。最终 SG 分析尚待完成。
🔗阅读/收听完整报道：https://buff.ly/fJHxF7X
8 浏览 · 0 赞 · 0 转发 · 0 回复
Durvalumab plus definitive chemoradiotherapy versus definitive chemoradiotherapy in patients with locally advanced esophagus carcinoma: ARION PRODIGE 67 randomized phase 2 trial
https://esmocongress.esmo.orgDurvalumab (D) in Combination With BCG Induction and Maintenance (I+M) for BCG-Naïve, High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC): Early Recurrence and Cystectomy-Free Survival in Patients (pts) With Papillary Only Tumours From POT
https://esmocongress.esmo.orgPerioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgShort-term preoperative durvalumab for stage I TNBC: First results from the phase II UNLOCK 14 - POP-DURVA trial
https://esmocongress.esmo.orgTarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.orgDurvalumab (D) plus carboplatin/paclitaxel (CP) followed by D with or without olaparib (O) in advanced/recurrent endometrial cancer (a/rEC): Interim overall survival (OS) and safety from the randomised phase 3 DUO-E/GOG-3041/ENGOT-EN10 stud
https://esmocongress.esmo.org来源：ScienceLink · x.com